Standard Family Office’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-11
Closed -$3K 94
2021
Q4
$3K Buy
+11
New +$2.83K 0.03% 163
2021
Q3
Sell
-11
Closed -$4K 121
2021
Q2
$4K Hold
11
﹤0.01% 275
2021
Q1
$3K Hold
11
﹤0.01% 345
2020
Q4
$3K Buy
+11
New +$2.84K ﹤0.01% 345

Other funds holding BIIB

Standard Family Office's BIIB Position: Q1 2022 in Review

Standard Family Office sold out of Biogen (BIIB) in Q1 2022, closing a stake of 11 shares — an estimated $3K sold.

Standard Family Office first reported a position in BIIB in Q4 2020 and held it in 4 quarters. The position peaked at $4K in Q2 2021. 952 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

  • Standard Family Office reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
  • Standard Family Office sold 11 Biogen shares in Q1 2022, an estimated $3K.
  • Standard Family Office first reported a position in Biogen in Q4 2020 and held it in 4 quarters.
  • Standard Family Office's Biogen position peaked at $4K in Q2 2021.
  • 952 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Standard Family Office's 13F filing for Q1 2022, filed 16 May 2022.